GlassScriptPhysician profile
Scott W Pinegar
NPI 1174009567
$11,128.61
in general payments reported to CMS, 2019-2025
32 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $357 · 2023: $4,075 · 2024: $3,325 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,478 · Consulting Fee: $756 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,477.89 |
| Consulting Fee | $756.00 |
| Education | $155.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,779.88 | 2021-2025 | |
| Gilead Sciences, INC. | $1,203.31 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,046.01 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $816.44 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $633.73 | 2021-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $537.64 | 2023-2025 | Omvoh |
| Genzyme Corporation | $458.45 | 2022-2025 | |
| Qol Medical, LLC | $442.54 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $392.23 | 2023-2024 | Zeposia |
| Pfizer INC. | $388.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.84 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $317.86 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $293.87 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Intercept Pharmaceuticals, INC. | $242.08 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $198.69 | 2025 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $177.76 | 2023-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $128.26 | 2024-2025 | Iqirvo |
| Organon LLC | $117.44 | 2022-2024 | Renflexis |
| Nestle Healthcare Nutrition INC. | $114.33 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $82.11 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $75.07 | 2024 | Voquezna |
| Pharming Healthcare, INC. | $46.06 | 2022 | |
| Digestive Care, INC. | $43.31 | 2023 | Pertzye |
| Novo Nordisk INC | $39.31 | 2024-2025 | Wegovy |
| Fresenius Kabi USA, LLC | $35.15 | 2023-2024 | Idacio |
| Orphalan INC | $34.61 | 2025 | Cuvrior |
| Travere Therapeutics, INC. | $21.20 | 2021 | |
| Mylan Institutional INC. | $19.35 | 2023 | |
| Vivus LLC | $19.02 | 2025 | Pancreaze |
| Exact Sciences Corporation | $17.79 | 2024 | |
| Braintree Laboratories, INC. | $17.05 | 2023 | Sutab |
| Daiichi Sankyo INC. | $15.58 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pinegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.